Toripalimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Toripalimab
DrugBank Accession Number
DB15043
Background

Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).

Type
Biotech
Groups
Investigational
Synonyms
  • Toripalimab
External IDs
  • JS 001
  • JS-001
  • JS001

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UProgrammed cell death protein 1
inhibitor
antibody
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8JXN261VVA
CAS number
1924598-82-2

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentRecurrent or Metastatic NPC1
3Not Yet RecruitingTreatmentLocally Advanced or Metastatic Urothelial Carcinoma1
3Not Yet RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3Not Yet RecruitingTreatmentRecurrent Nasopharyngeal Carcinoma1
3Not Yet RecruitingTreatmentResectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma1
3RecruitingPreventionLynch Syndrome1
3RecruitingTreatmentAdvanced Hepatocellular Carcinoma (HCC)2
3RecruitingTreatmentAdvanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy1
3RecruitingTreatmentChemotherapy / Nasopharyngeal Carcinoma / PD-1 Treatment / Radiotherapy1
3RecruitingTreatmentGeneral Surgery / Nasopharyngeal Carcinoma / PD-11

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Antibody
General Function
Signal transducer activity
Specific Function
Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. ...
Gene Name
PDCD1
Uniprot ID
Q15116
Uniprot Name
Programmed cell death protein 1
Molecular Weight
31646.635 Da

Drug created on May 20, 2019 14:44 / Updated on February 21, 2021 18:55